DE69724328D1 - Konjugate von einem Interleukin-2 Rezeptor spezifisch erkennenden Faktor mit Ribonuklease - Google Patents

Konjugate von einem Interleukin-2 Rezeptor spezifisch erkennenden Faktor mit Ribonuklease

Info

Publication number
DE69724328D1
DE69724328D1 DE69724328T DE69724328T DE69724328D1 DE 69724328 D1 DE69724328 D1 DE 69724328D1 DE 69724328 T DE69724328 T DE 69724328T DE 69724328 T DE69724328 T DE 69724328T DE 69724328 D1 DE69724328 D1 DE 69724328D1
Authority
DE
Germany
Prior art keywords
ribonuclease
interleukin
conjugates
receptor specific
specific recognizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69724328T
Other languages
English (en)
Other versions
DE69724328T2 (de
Inventor
Masakazu Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NBT CORP., KOCHI, JP
Original Assignee
Daiichi Suntory Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd filed Critical Daiichi Suntory Pharma Co Ltd
Publication of DE69724328D1 publication Critical patent/DE69724328D1/de
Application granted granted Critical
Publication of DE69724328T2 publication Critical patent/DE69724328T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69724328T 1996-06-05 1997-06-04 Konjugate von einem Interleukin-2 Rezeptor spezifisch erkennenden Faktor mit Ribonuklease Expired - Fee Related DE69724328T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8142485A JPH09324000A (ja) 1996-06-05 1996-06-05 インターロイキン−２受容体を特異的に認識する因子とリボヌクレアーゼとの接合体
JP14248596 1996-06-05

Publications (2)

Publication Number Publication Date
DE69724328D1 true DE69724328D1 (de) 2003-10-02
DE69724328T2 DE69724328T2 (de) 2004-08-19

Family

ID=15316427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724328T Expired - Fee Related DE69724328T2 (de) 1996-06-05 1997-06-04 Konjugate von einem Interleukin-2 Rezeptor spezifisch erkennenden Faktor mit Ribonuklease

Country Status (4)

Country Link
EP (1) EP0811385B1 (de)
JP (1) JPH09324000A (de)
AT (1) ATE247983T1 (de)
DE (1) DE69724328T2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018300069A1 (en) 2017-07-11 2020-02-27 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20200181220A1 (en) 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
CN114949240A (zh) 2019-02-06 2022-08-30 新索思股份有限公司 Il-2缀合物及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting

Also Published As

Publication number Publication date
EP0811385A3 (de) 1998-05-13
EP0811385B1 (de) 2003-08-27
ATE247983T1 (de) 2003-09-15
EP0811385A2 (de) 1997-12-10
DE69724328T2 (de) 2004-08-19
JPH09324000A (ja) 1997-12-16

Similar Documents

Publication Publication Date Title
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
HU891055D0 (en) Ultrasonic contrast materials, process for their preparation and for their use as diagnostical and therapeutical drugs
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
FI905718A0 (fi) Transdermalt medel.
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DE59009462D1 (de) Implantierbare Vorrichtung zur dosierten Abgabe von Medikamenten in den menschlichen Körper.
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
DE69724328D1 (de) Konjugate von einem Interleukin-2 Rezeptor spezifisch erkennenden Faktor mit Ribonuklease
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ATE89288T1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti- cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
DE3788888D1 (de) Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
RU99116456A (ru) Лекарственное средство для профилактики и лечения вирусных болезней животных
IT8622051A0 (it) Composizioni farmaceutiche adattivita' cicatrizzante.
ATE64305T1 (de) Antikrebstherapie und zytotoxische arzneimittel fuer deren implementation.
RU96102195A (ru) Лекарственное средство

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NBT CORP., KOCHI, JP

8339 Ceased/non-payment of the annual fee